Elevai Labs, Inc. Common Stock (ELAB) - Total Assets
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) holds total assets worth $36.56 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Elevai Labs, Inc. Common Stock - Total Assets Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Elevai Labs, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Elevai Labs, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Elevai Labs, Inc. Common Stock's total assets of $36.56 Million consist of 53.4% current assets and 46.6% non-current assets. Review Elevai Labs, Inc. Common Stock total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.0% |
| Accounts Receivable | $340.53K | 2.7% |
| Inventory | $95.10K | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.89 Million | 22.5% |
| Goodwill | $977.77K | 7.6% |
Asset Composition Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Elevai Labs, Inc. Common Stock share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elevai Labs, Inc. Common Stock's current assets represent 53.4% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2025, down from 78.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 22.5% of total assets.
Elevai Labs, Inc. Common Stock Competitors by Total Assets
Key competitors of Elevai Labs, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Elevai Labs, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.36 | 22.38 | 2.55 |
| Quick Ratio | 1.30 | 22.38 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.50 Million | $6.98 Million | $913.05K |
Elevai Labs, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Elevai Labs, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 43.1% |
| Total Assets | $12.87 Million |
| Market Capitalization | $3.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Elevai Labs, Inc. Common Stock's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Elevai Labs, Inc. Common Stock's assets grew by 43.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Elevai Labs, Inc. Common Stock (2020–2025)
The table below shows the annual total assets of Elevai Labs, Inc. Common Stock from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.87 Million | +43.09% |
| 2024-12-31 | $8.99 Million | +73.28% |
| 2023-12-31 | $5.19 Million | +174.28% |
| 2022-12-31 | $1.89 Million | +184.00% |
| 2021-12-31 | $666.25K | +3814.05% |
| 2020-12-31 | $17.02K | -- |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing … Read more